Increasing dose of radioactive iodine in Graves' disease with historical control

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

TCTR

Registry ID

TCTR20220322002

Enrollment

220

Registered

2022-03-22

Start date

2022-07-01

Completion date

Unknown

Last updated

2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Graves&#039

Interventions

Radioactive iodine 20 mCi, capsule, oral, single dose,Radioactive iodine 10-15 mCi, capsule, oral, single dose

Experimental Radiation,Active Comparator Radiation

Radioactive iodine 20 mCi,Radioactive iodine 10-15 mCi

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Patiens with a diagnosis of Graves' disease in ICD10 code 2. Age 18 or older

Exclusion criteria

Exclusion criteria: 1. Pregnancy or lactation 2. Received previous radioactive iodine or surgery 3. Co-existing or suspicious thyroid cancer 4. Active or severe Graves' orbitopathy 5. Hyperthyroidism from other causes such as toxic adenoma, toxic multinodular goiter or thyroiditis

Design outcomes

Primary

Measure	Time frame
Remission At 6 months after the intervention Thyroid fuction test	—

Secondary

Measure	Time frame
Time to remission At 6 months after the intervention Thyroid function test	—

Countries

Thailand

Contacts

Public ContactWasit Kanokwongnuwat

Prapokklao Hospital

wasitov@gmail.com039319666

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Apr 4, 2026

Increasing dose of radioactive iodine in Graves&#039; disease with historical control